Insulet Hires Flavia Pease as Finance Chief

Insulet announced that Flavia Pease will succeed Ana Maria Chadwick as executive VP and chief financial officer (CFO) effective September 30. Chadwick will become a senior advisor to Insulet for a smooth transition.

“I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth,” said Ashley McEvoy, Insulet’s president and CEO. “She has been instrumental in strengthening our financial foundation and positioning us for continued success.”

“It has been a privilege to help advance Insulet’s mission,” added Chadwick. “I am confident in the team and the company’s continued momentum.”

Pease was most recently corporate executive VP and CFO at Charles River Laboratories. Before that, she spent 23 years at Johnson & Johnson, working in the Medical Devices and Pharmaceuticals segments. During her tenure, she was VP and CFO of J&J’s global Medical Devices business, and VP of finance for Janssen North America.

She began her career at Johnson & Johnson in 1998 with the LifeScan business and earlier held positions at SC Johnson and in investment banking in Brazil. Pease has also been a member of Insulet’s board of directors since January 2024—she will resign from the board upon moving to the CFO role.

“Flavia is a highly accomplished business leader with world-class healthcare and MedTech expertise,” said McEvoy. “Her extensive leadership experience in complex global organizations, proven ability to drive financial performance through disciplined execution of the Company’s strategy, and track record of value creation for all stakeholders make her the ideal CFO to help guide Insulet’s next phase of patient-centric growth. Her contributions as a member of the Board have already been instrumental to our strong performance and will enable a seamless transition.”

“I am thrilled to join this talented leadership team as CFO and to continue serving this outstanding company,” said Pease. “Insulet’s commitment to improving the lives of people with diabetes is deeply inspiring, and I look forward to partnering with Ashley, the Board, and the Insulet team to build on the Company’s strong foundation, accelerate growth, and deliver lasting value for customers and shareholders.”

Last month, the company revealed it had promoted Eric Benjamin as its new chief operating officer and appointed Manoj Raghunandanan as chief growth officer.